IZ 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. IZ 200 Capsule is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and candidiasis. It is particularly effective against infections caused by dermatophytes, yeasts, and molds. The capsule formulation allows for oral administration, with absorption enhanced when taken with food. Dosage and duration of therapy depend on the type and severity of infection and should be determined by a healthcare professional. Caution is advised in patients with hepatic impairment or congestive heart failure, as itraconazole may cause hepatotoxicity and negative inotropic effects. Potential drug interactions should be carefully reviewed due to itraconazole’s inhibition of cytochrome P450 enzymes. Monitoring liver function tests during prolonged therapy is recommended to ensure patient safety.